P21-Activated Kinase: Role in Gastrointestinal Cancer and Beyond

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2022 Oct 14

PMID 36230657

Authors

Xiaodong Li

Feng Li

Affiliations

Soon will be listed here.

Abstract

Gastrointestinal tumors are the most common tumors, and they are leading cause of cancer deaths worldwide, but their mechanisms are still unclear, which need to be clarified to discover therapeutic targets. p21-activating kinase (PAK), a serine/threonine kinase that is downstream of Rho GTPase, plays an important role in cellular signaling networks. According to the structural characteristics and activation mechanisms of them, PAKs are divided into two groups, both of which are involved in the biological processes that are critical to cells, including proliferation, migration, survival, transformation and metabolism. The biological functions of PAKs depend on a large number of interacting proteins and the signaling pathways they participate in. The role of PAKs in tumors is manifested in their abnormality and the consequential changes in the signaling pathways. Once they are overexpressed or overactivated, PAKs lead to tumorigenesis or a malignant phenotype, especially in tumor invasion and metastasis. Recently, the involvement of PAKs in cellular plasticity, stemness and the tumor microenvironment have attracted attention. Here, we summarize the biological characteristics and key signaling pathways of PAKs, and further analyze their mechanisms in gastrointestinal tumors and others, which will reveal new therapeutic targets and a theoretical basis for the clinical treatment of gastrointestinal cancer.

Citing Articles

The up-regulation of PAK2 indicates unfavorable prognosis in patients with serous epithelial ovarian cancer and contributes to paclitaxel resistance in ovarian cancer cells.

Shuang T, Wu S, Zhao Y, Yang Y, Pei M BMC Cancer. 2024; 24(1):1213.

PMID: 39350056 PMC: 11440729. DOI: 10.1186/s12885-024-12969-1.

FRAX486, a PAK inhibitor, overcomes ABCB1-mediated multidrug resistance in breast cancer cells.

Zhang M, Zeng X, She M, Dong X, Chen J, Xiong Q Braz J Med Biol Res. 2024; 57:e13357.

PMID: 38958364 PMC: 11221864. DOI: 10.1590/1414-431X2024e13357.

Targeting P21-Activated Kinase-1 for Metastatic Prostate Cancer.

Somanath P, Chernoff J, Cummings B, Prasad S, Homan H Cancers (Basel). 2023; 15(8).

PMID: 37190165 PMC: 10137274. DOI: 10.3390/cancers15082236.

Hyperactivation of p21-Activated Kinases in Human Cancer and Therapeutic Sensitivity.

Sankaran D, Amjesh R, Paul A, George B, Kala R, Saini S Biomedicines. 2023; 11(2).

PMID: 36830998 PMC: 9953343. DOI: 10.3390/biomedicines11020462.

References

Sells M, Chernoff J . Emerging from the Pak: the p21-activated protein kinase family. Trends Cell Biol. 1997; 7(4):162-7. DOI: 10.1016/S0962-8924(97)01003-9. View

Ghosh A, Awasthi S, Peterson J, Hamburger A . Regulation of tamoxifen sensitivity by a PAK1-EBP1 signalling pathway in breast cancer. Br J Cancer. 2013; 108(3):557-63. PMC: 3593557. DOI: 10.1038/bjc.2013.11. View

Chung J, Kim T, Kang Y, Yoon S, Kim Y, Lee S . PAK1 as a Potential Therapeutic Target in Male Smokers with EGFR-Mutant Non-Small Cell Lung Cancer. Molecules. 2020; 25(23). PMC: 7729550. DOI: 10.3390/molecules25235588. View

Oladimeji P, Skerl R, Rusch C, Diakonova M . Synergistic Activation of ERα by Estrogen and Prolactin in Breast Cancer Cells Requires Tyrosyl Phosphorylation of PAK1. Cancer Res. 2016; 76(9):2600-11. PMC: 4873454. DOI: 10.1158/0008-5472.CAN-15-1758. View

Zhang J, Zhang H, Wang J, You L, Zhou R, Zhao D . GL-1196 Suppresses the Proliferation and Invasion of Gastric Cancer Cells via Targeting PAK4 and Inhibiting PAK4-Mediated Signaling Pathways. Int J Mol Sci. 2016; 17(4):470. PMC: 4848926. DOI: 10.3390/ijms17040470. View

Zhu Y, Liu H, Xu L, An H, Liu W, Liu Y . p21-activated kinase 1 determines stem-like phenotype and sunitinib resistance via NF-κB/IL-6 activation in renal cell carcinoma. Cell Death Dis. 2015; 6:e1637. PMC: 4669810. DOI: 10.1038/cddis.2015.2. View

King H, Thillai K, Whale A, Arumugam P, ElDaly H, Kocher H . PAK4 interacts with p85 alpha: implications for pancreatic cancer cell migration. Sci Rep. 2017; 7:42575. PMC: 5312077. DOI: 10.1038/srep42575. View

Liu Y, Chen N, Cui X, Zheng X, Deng L, Price S . The protein kinase Pak4 disrupts mammary acinar architecture and promotes mammary tumorigenesis. Oncogene. 2010; 29(44):5883-94. PMC: 2974003. DOI: 10.1038/onc.2010.329. View

Jang I, Jeon B, Jeong E, Kim E, Kang D, Lee J . Pak1/LIMK1/Cofilin Pathway Contributes to Tumor Migration and Invasion in Human Non-Small Cell Lung Carcinomas and Cell Lines. Korean J Physiol Pharmacol. 2012; 16(3):159-65. PMC: 3394917. DOI: 10.4196/kjpp.2012.16.3.159. View

10.

Wang G, Song Y, Liu T, Wang C, Zhang Q, Liu F . PAK1-mediated MORC2 phosphorylation promotes gastric tumorigenesis. Oncotarget. 2015; 6(12):9877-86. PMC: 4496403. DOI: 10.18632/oncotarget.3185. View

11.

Wu D, Wu T, Chen C, Lee H . PAK1 Is a Novel Therapeutic Target in Tyrosine Kinase Inhibitor-Resistant Lung Adenocarcinoma Activated by the PI3K/AKT Signaling Regardless of EGFR Mutation. Clin Cancer Res. 2016; 22(21):5370-5382. DOI: 10.1158/1078-0432.CCR-15-2724. View

12.

Cosset E, Ilmjarv S, Dutoit V, Elliott K, Von Schalscha T, Camargo M . Glut3 Addiction Is a Druggable Vulnerability for a Molecularly Defined Subpopulation of Glioblastoma. Cancer Cell. 2017; 32(6):856-868.e5. PMC: 5730343. DOI: 10.1016/j.ccell.2017.10.016. View

13.

Topalian S, Drake C, Pardoll D . Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 2015; 27(4):450-61. PMC: 4400238. DOI: 10.1016/j.ccell.2015.03.001. View

14.

Jiang Y, Liu W, Li T, Hu Y, Chen S, Xi S . Prognostic and Predictive Value of p21-activated Kinase 6 Associated Support Vector Machine Classifier in Gastric Cancer Treated by 5-fluorouracil/Oxaliplatin Chemotherapy. EBioMedicine. 2017; 22:78-88. PMC: 5552213. DOI: 10.1016/j.ebiom.2017.06.028. View

15.

Yeo D, He H, Patel O, Lowy A, Baldwin G, Nikfarjam M . FRAX597, a PAK1 inhibitor, synergistically reduces pancreatic cancer growth when combined with gemcitabine. BMC Cancer. 2016; 16:24. PMC: 4715347. DOI: 10.1186/s12885-016-2057-z. View

16.

Martin G, Bollag G, McCormick F, Abo A . A novel serine kinase activated by rac1/CDC42Hs-dependent autophosphorylation is related to PAK65 and STE20. EMBO J. 1995; 14(9):1970-8. PMC: 398296. DOI: 10.1002/j.1460-2075.1995.tb07189.x. View

17.

Sorrenson B, Dissanayake W, Hu F, Lee K, Shepherd P . A role for PAK1 mediated phosphorylation of β-catenin Ser552 in the regulation of insulin secretion. Biochem J. 2021; 478(8):1605-1615. DOI: 10.1042/BCJ20200862. View

18.

Li D, Zhang Y, Li Z, Wang X, Qu X, Liu Y . Activated Pak4 expression correlates with poor prognosis in human gastric cancer patients. Tumour Biol. 2015; 36(12):9431-6. DOI: 10.1007/s13277-015-3368-4. View

19.

Chauhan S, Ebeling M, Maher D, Koch M, Watanabe A, Aburatani H . MUC13 mucin augments pancreatic tumorigenesis. Mol Cancer Ther. 2011; 11(1):24-33. PMC: 4100478. DOI: 10.1158/1535-7163.MCT-11-0598. View

20.

Huynh N, Shulkes A, Baldwin G, He H . Up-regulation of stem cell markers by P21-activated kinase 1 contributes to 5-fluorouracil resistance of colorectal cancer. Cancer Biol Ther. 2016; 17(8):813-23. PMC: 5004687. DOI: 10.1080/15384047.2016.1195045. View